Bayer and DelSiTech announce ophthalmology technology collaboration

Pharmaceutical Company Product News

Bayer has announced a new collaboration with the Finnish drug delivery technology and drug development company DelSiTech in the field of ophthalmology.

The collaboration and technology licence agreement will see the companies work together on the worldwide application of DelSiTech's Silica Matrix drug delivery platform to a number of Bayer's ophthalmology compounds.

“Bayer is allying with DelSiTech to deliver innovative drug delivery technology for ophthalmology applications.“

This builds on a longstanding relationship between the companies and underlines both organisations' belief in the potential applications of biodegradable silica material in challenging drug delivery applications.

DelSiTech will receive milestone payments based on the successful completion of different stages of the development, commercialisation and sales process. Bayer, meanwhile, has agreed to fund all development and commercialisation costs of the collaborative projects.

Professor Andreas Busch, member of the executive committee for Bayer's pharmaceuticals division and head of drug discovery, said: "This partnership with DelSiTech underlines Bayer's continued commitment to leverage collaborations on cutting-edge science in ophthalmology, with the aim to improve the quality of life for patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news

Tags